We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 05 AUGUST 2015
Recent Developments On Patent-Eligibility Of Medical Use Claims In Canada
Goudreau Gage Dubuc
Last December, the Federal Court of Canada overturned a decision of the Commissioner of Patents to refuse a patent claiming a fixed dosage regimen for the drug Humira® (Adalimunab) used in rheumatoid arthritis.
CanadaIntellectual Property






